Drug manufacturer Bristol Myers Squibb (BMS) yesterday updated its 340B contract pharmacy pricing policy to address how it will handle 340B discounts on its new heart medicine Camzyos, a potential blockbuster product.
Camzyos is a first-in-class treatment for symptomatic obstructive hypertrophic cardiomyopathy. To minimize the risk of patient heart failure and/or fetal harm, its distribution is limited under a Risk Evaluation and Mitigation Strategy (REMS). It can be dispensed only by certified pharmacies only to authorized patients.
Drug manufacturer Bristol Myers Squibb (BMS) yesterday updated its 340B contract pharmacy pricing policy to address how it will handle 340B discounts on its new heart medicine Camzyos, a potential blockbuster product.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
